Kamisha L. Johnson-Davis, PhD, MBA, DABCC (CC, TC)

Professor (Clinical), University of Utah School of Medicine

Specialties

• Therapeutic drug monitoring
• Drug screening
• Neonatal drug testing
• Trace and toxic elements

Education

• Doctorate Degree—Pharmacology, University of Utah
• Postdoctoral Fellowship—Center for Human Toxicology, University of Utah
• Postdoctoral Fellowship—Clinical Chemistry, University of Utah
• Master’s Degree—Business Administration, University of Utah

Certification/Affiliations

• American Board of Clinical Chemistry (Clinical Chemistry, Toxicological Chemistry)
• Certification of Qualification, New York State Department of Health

Research Interests

• Assay development for drug testing by mass spectrometry and immunoassay
• Therapeutic drug monitoring in pediatric and adult patients
• Drug testing in alternative matrices and remote sampling

Awards

• Travel Scholarship, AAMC Minority Faculty Career Development Seminar, 2014
• International Travel Grant, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), 16th Congress, 2018

Recent Publications

• Smith K, Genesi BT, Boyd JM, et al. Improvements, challenges, and the investigation of two unknowns in arsenic urine speciation analysis by HPLC-ICP-MS: from development to post-implementation. Ther Drug Monit. Published online Dec 2025.
• Shean RC, Johnson-Davis KL. Broad-spectrum drug screening positivity rates in pediatrics and adults: the reference laboratory perspective. Ther Drug Monit. Published online Oct 2025.
• Adegoke AO, Jackson AN, Laulu SL, et al. Immunalysis tapentadol assay reformulation resolves tramadol interference. J Anal Toxicol. 2025;49(9):713-718.
• Mathewson NJ, Okoye NC, Nelson HA, et al. Beyond the baseline: quantification of two phosphatidylethanol homologues in whole blood by LC-MS-MS and retrospective data analysis from a national reference laboratory. J Anal Toxicol. 2025;49(3):191-200.
• Bithi N, Ricks D, Walker BS, et al. Method validation of an inductively coupled plasma mass spectrometry (ICP-MS) assay for the analysis of magnesium, copper and zinc in red blood cells. J Mass Spectrom Adv Clin Lab. 2024;34:21-27.
• Masuda S, Lemaitre F, Barten MJ, et al. Everolimus personalized therapy: second consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2025;47(1):4-31.
• Snozek CLH, Yee CI, Bryksin J, et al. Assessing knowledge gaps and educational needs in urine drug test interpretation among health care professionals. Am J Clin Pathol. 2025;163(1):69-79.
• Baryeh K, Zhou R, Brown E, et al. Retrospective data analysis reveals unusual metabolism pattern of ethanol in pediatrics as compared to adult and geriatric populations. J Appl Lab Med. 2024;9(4):767-775.
• McMillin GA, Morad AW, Boyd JM, et al. Biological testing and interpretation of laboratory results associated with detecting newborns with substance exposure. Clin Chem. 2024;70(7):934-947.
• Johnson-Davis KL, Ly D. Quantification of olanzapine by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Methods Mol Biol. 2024;2737:347-357.
• Johnson-Davis KL, Thomas RL. Quantification of oxcarbazepine using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Methods Mol Biol. 2024;2737:387-395.
• Pandya V, Wilker C, Johnson-Davis KL. Longitudinal trends in meconium drug detection in 46 US states between the years 2015 and 2020. J Anal Toxicol. 2023;47(6):495-503.
• Okoye NC, Zuromski LM, Johnson-Davis KL. Trends in blood lead levels quantified by ICP-MS: a reference laboratory retrospective study. J Appl Lab Med. 2023;8(5):909-916.
• Lemaitre F, Budde K, Van Gelder T, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19. Ther Drug Monit. 2023;45(2):191-199.
• Smith K, Johnson-Davis KL, Shahrokh K. A new broad-spectrum drug screen for 127 analytes by LC-MS/MS. J Appl Lab Med. 2023;8(2):240-250.
• Bajaj AO, Parker R, Farnsworth C, et al. Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS). J Mass Spectrom Adv Clin Lab. 2022;27:33-39.
• Bajaj AO, Ly D, Johnson-Davis KL. Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. J Mass Spectrom Adv Clin Lab. 2022;24:100-106.
• Bajaj AO, Kushnir MM, Kish-Trier E, et al. LC-MS/MS method for measurement of thiopurine nucleotides (TN) in erythrocytes and association of TN concentrations with TPMT enzyme activity. Front Pharmacol. 2022;13:836812.
• Hunsaker JJH, La’ulu SL, LaGrave D, et al. Tobacco and cannabis use during pregnancy. Am J Clin Pathol. 2022;157(1):146-152.
• Clarke WA, Salyer B, Hussey C, et al. Multi-site evaluation of immunoassays for antipsychotic drug measurement in clinical samples. J Appl Lab Med. 2021;6(6):1541-1550.
• Okoye NC, Greene DN, Johnson-Davis KL. Is the confirmatory test always right? Sometimes immunoassays know what they are talking about. J Appl Lab Med. 2022;7(2):607-612.
• Kroner GM, Thomas RL, Johnson-Davis KL. Retrospective analysis of pediatric and adult populations using an LC-MS/MS method for oxcarbazepine/eslicarbazepine metabolite. J Appl Lab Med. 2021;6(3):637-644.
• Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43(2):150-200.
• McMillin GA, Johnson-Davis KL, Kelly BN, et al. Impact of the opioid epidemic on drug testing. Ther Drug Monit. 2021;43(1):14-24.